跳至主要内容
临床试验/TCTR20200708006
TCTR20200708006已完成3 期

Efficacy of Olanzapine 5 mg versus 10 mg for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving High Emetic Risk Chemotherapy,without Neurokinin-1 Receptor Antagonist

one0 个研究点目标入组 140 人开始时间: 2020年7月8日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
one
入组人数
140

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • 1. Age ≥ 18 year-old
  • 2. Receiving the first cycle of doxorubicin/cyclophosphamide or high-dose cisplatin (≥70mg/m2)
  • 3. Eastern Cooperative Oncology Group performance status 0 to 2
  • 4. Adequate organ function (absolute neutrophil count ≥2000 cell/uL, aminotransferase < 100 IU/L, total bilirubin<2.0 mg/dl and creatinine clearance >50 ml/min)

排除标准

  • 1. Symptomatic Brain Metastasis
  • 2. Pregnancy or Breast-feeding
  • 3. Allergy to agents in the study
  • 4. Receiving anticonvulsants or fluoro-quinolone antibiotic
  • 5. History of receiving NK-1 RA, 5-HT3 receptor antagonists, dexamethasone, dopamine receptor antagonists, antihistamines, benzodiazepine and antipsychotics in 48-hour, previously
  • 6. Receiving abdominal radiotherapy
  • 7. History of heart disease or arrhythmia or uncontrolled heart failure or acute myocardial infarction in 6 months previously or uncontrolled diabetes

研究者

发起方
one

相似试验